Stockreport

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Rallybio Corporation  (RLYB) 
PDF — First Ever Trial in Pregnant Women at Higher Risk of Alloimmunization and FNAIT —— Screening in the Phase 2 Clinical Trial On Track to Initiate in 4Q 2024 — NEW HAV [Read more]